How Lynovex works to boost antibiotics in combatting Pseudomonas aeruginosa infection in cystic fibrosis

Our paper describing the mechanism of action of the active ingredient of Lynovex against Pseudomonas aeruginosa and other bacteria (in CF and other conditions) has been accepted for publication in the journal Infection and Immunity.  Excellent work by our Principal Scientist Dr Douglas Fraser-Pitt and team.

"Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection". Douglas Fraser-Pitt, Derry Mercer, Daniel Smith, Aleksandra Kowalczuk, Jennifer Robertson, Emma Lovie, Peter Perenyi, Michelle Cole, Michel Doumith, Robert Hill, Katie Hopkins, Neil Woodford, and Deborah O'Neil.